Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

The new pill is seen as a ‘major leap forward’ for hundreds of patients living with the rarest forms of cystic fibrosis ...